Skip to main content
. 2021 Jul 7;9(7):787. doi: 10.3390/biomedicines9070787

Figure 4.

Figure 4

Effects of omalizumab on the DNAse I activity in airway epithelial cells. (A,B) Purified peripheral blood eosinophils co-incubated with BEAS-2B cells were treated with omalizumab (10 μg/mL) overnight. The proportions of Annexin-V-positive eosinophils (A) and CD69 expression on eosinophils (B) were evaluated. (C) BEAS-2B cells co-incubated with purified peripheral blood eosinophils were treated with omalizumab (10 μg/mL) overnight. The DNAse I activity in BEAS-2B cell extracts was assayed. (D) Mucin co-incubated with BEAS-2B was treated with omalizumab (10 μg/mL) overnight. The mucin viscoelasticity was measured using a viscometer at 10 rpm. Values represent the means ± SEM values of four experiments; # p < 0.05, ## p < 0.01 (vs. non-treatment control), * p < 0.05 (as shown between the two groups).